期刊文献+

干细胞移植治疗心力衰竭的临床研究进展

Stem cell transplantation for treatment of heart failure
原文传递
导出
摘要 近年来,药物、器械和外科手术治疗心力衰竭的进展相对滞缓,干细胞移植治疗逐步成为这一领域新的热点。目前的临床研究对干细胞移植治疗心力衰竭的疗效尚无定论。随着大规模、随机、双盲、安慰剂对照、多中心临床试验的进一步开展和移植策略的优化,干细胞移植将可能成为治疗心力衰竭极富前景的新手段。 Summary Recently, slow progress was attained in the field of the treatment for heart failure by drugs, device and surgery. However, significant strides have been made by investigators in the study of stem cell therapy for heart failure. Thus far, the efficacy of stern cell therapy for the treatment of heart failure in clinical trials remains controversial. Larger randomized, double-blind, placebo-controlled, multicenter trials were warranted to be performed to improve the efficacy and safety, while the therapeutic strategy of stem cell transplantation holds great promise for the treatment of heart failure.
作者 苏冠华 程翔
出处 《临床心血管病杂志》 CAS CSCD 北大核心 2012年第10期721-723,共3页 Journal of Clinical Cardiology
关键词 心肌梗死 干细胞 移植 心力衰竭 缺血性心肌病 myocardial infarction stem cell cell transplantation heart failure ischemic cardiomyopathy
  • 相关文献

参考文献12

  • 1BOI.LI R, CHUGH A R, DAMARIO D, et al. Cardiac stem cells in patients with ischaemic cardiomyop- athy (SCIPIO) : initial results of a randomised phase 1 trial[J]. Lancet, 2011,378 : 1847- 1857.
  • 2MAKKAR R R, SMITH R R, CHENG K, et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS) : a prospective, randomised phase 1 trial[J]. Lancet, 2012,379:895-904.
  • 3HU S, I.IU S, ZHENG Z, et al. Isolated coronary artery bypass graft combined with bone marrow mononuclcar cells delivered through a graft vessel for patients with previous myocardial infarction and chro- nic heart failure: a single-center, randomized, double blind, placebo-controlled clinical trial[J]. J Am Coll Cardiol, 2011,57 ..2409-2415.
  • 4TRAVENSE J H, HENRY T D, ELLIS S G, et al. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial [J]. JAMA, 2011, 306..2110-2119.
  • 5PERIN E C, WILLERSON J T, PEPINE C J, et al. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial[J]. JAMA,2012, 307:1717-1726.
  • 6BARTUNEK J, WIJNS W, DOLATABADI D, et al.C-CURE rnulticenter trial: lineage specified bone marrow derived cardiopoietie mesenchymal stem cells for treatment of ischemic eardiomyopathy[J]. J Am Coll Cardiol, 2011,57 : E200-205.
  • 7MENASCHE P, ALFIERI O, JANSSENS S, et al. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation[J]. Circulation, 2008,117 : 1189 - 1200.
  • 8VELTMAN C E, SOLIMAN O I, GELEIJNSE M L, et al. Four-year follow-up of treatment with intramyocardial skeletal myoblasts injection in patients with ischaemic cardiomyopathy[J]. Eur Heart J, 2008,29: 1386-1396.
  • 9DIB N, DINSMORE J, LABABIDI Z, et al. One- year follow-up of feasibility and safety of the first U. S. , randomized, controlled study using 3-dimensional guided catheter-based delivery of autologous skeletal myoblasts for ischemic cardiomyopathy (CAuSMIC study) [J]. JACC Cardiovasc Interv, 2009,2 : 9- 16.
  • 10FUJITA T, SAKAGUCHI T, MIYAGAWA S, et al. Clinical impact of combined transplantation of autologous skeletal myoblasts and bone marrow mononuclear cells in patients with severely deteriorated is- chemic cardiomyopathy [J]. Surg Today, 2011, 41; 1029-1036.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部